| HOME >> BIOLOGY >> TECHNOLOGY |
Except for historical and factual information contained herein, this
press release contains forward-looking statements, such as revenue growth
rates and cash flow projections, operating performance and acceptance of
ICG technology, the accuracy of which is necessarily subject to
uncertainties and risks, including the Company's ability to meet its short
and long-term liquidity and capital needs, primary dependence on the
BioZ(R) product line, and various uncertainties characteristic of early
stage companies, as well as other risks detailed in the Company's filings
with the SEC, including its 2007 Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Future events and actual results could differ
materially from the forward-looking statements. Readers are urged not to
place undue reliance on forward-looking statements. The Company does not
undertake to update the disclosures contained in this press release.
CardioDynamics International Corporation
In thousands, except per share data (unaudited)
Selected Consolidated Operational Three Months Nine Months
Results Ended Ended
August 31, August 31,
2008 2007 2008 2007
Net sales $6,066 $5,591 $18,008 $15,699
Cost of sales 1,519 1,554 5,066 4,740
Gross margin 4,547 4,037 12,942 10,959
Research and development 386 420 1,070 1,317
Selling and marketing 3,669 3,977 11,112 11,101
General and administrative 714 772 2,246 2,437
Amortization of intangible assets 32 30 96 115
Loss from operations (2
'/>"/>
| SOURCE CardioDynamics Copyright©2008 PR Newswire. All rights reserved |